Melinta Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Melinta Therapeutics, Inc.
Deal Watch: Novartis Acquires Gene Therapy Candidate From AvroBio
AvroBio retains rights to its other HSC gene therapy candidates. Alimera Acquires Further Commercial Rights To Eyepoint’s Uveitis Drug.
Cidara’s Novel Antifungal Approved For Antimicrobial-Resistant C. Auris Infections
Cidara’s US commercial partner Melinta will launch the novel echinocandin this summer, announcing pricing shortly before rollout. Limited indication follows recommendation of FDA advisory panel.
Elucid Brings Personalized Imaging Diagnostics To Cardiology
Elucid has developed machine learning models that can interpret a patient’s risk of stroke or cardiovascular events from angiography images.
Novel Brain Penetrant For Treating X-ALD Among Raft Of New EU Filings
Investigational products from Minoryx and a host of other companies targeting a range of diseases are now under review by the European Medicines Agency for potential EU approval.
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- Rib-X Pharmaceuticals, Inc.
- Cempra, Inc. (Cempra Pharmaceuticals, Inc.)
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.